Login
Navigate Fool.com
Will VNDA beat
the market?
Community Rating: 2 Stars: Unattractive

7.12 0.15 (2.15%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.86
Previous Close $6.97
Daily Range $6.36 - $7.26
52-Week Range $2.92 - $7.53
Market Cap $201.8M
P/E Ratio -8.20
Dividend (Yield) $0.00 (0.0%)
Volume 492,280
Average Daily Volume 460,295
Current FY EPS -$0.94

How do you think VNDA
will perform against the market?

Top VNDA Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted August 4, 2011

If you're looking around for falling knives to catch, may I recommend Vanda? The stock can never get any liftoff because royalties from their single product Fanapt have plateaued under 1M/quarter, and … More

0 Replies Reply Report this Post
 

hlacheen (< 20)
Submitted February 14, 2007

Utter garbage.... like most pharmaceutical companies with huge losses and horrible balance sheets.

1 Replies Reply Report this Post

News & Commentary

Avoid This Biotech Stock

Our investing community's latest prime pick to avoid: Chelsea Therapeutics

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

Vanda Drug Fails in Depression Study

Tasimelteon remains on track to as a potential treatment for non-24-hour sleep-wake disorder.

This Week in Biotech: Part 1

A look back at the biggest stories this week in biotech and what they mean for investors.

Four Companies That Stuck Out on Tuesday; and that Might Trade Higher

Today’s Market Winners and Losers

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

You Should Have Seen These Biotech Failures Coming

Microcap biotechs are a value for a reason.

The Big Bet on Cell Therapeutics

Will the FDA change its mind about pixantrone?

Avoid This Biotech Stock

Our investing community's latest prime pick to Avoid -- Somaxon Pharmaceuticals.

See More VNDA News...

Sector

Healthcare

Industry

Drugs

Vanda Pharmaceuticals, Inc. (VNDA) Description

A biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders. Website: http://www.vandapharmaceuticals.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks